Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: Results of the MILOR study

Journal of the European Academy of Dermatology and Venereology

Volumn 12, Issue 1, 1999, Pages 16-24

  Dubertret, L ^a   Murrieta Aguttes, M ^b   Tonet, J ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b SANOFI   (France)

^c HÔPITAL CHARLES FOIX   (France)

Author keywords

Antihistamines; Chronic idiopathic urticaria; H1 Antagonists; Loratadine; Mizolastine; Placebo

Indexed keywords

LORATADINE; MIZOLASTINE;

ADULT; AGED; ARTICLE; ASTHENIA; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; APPENDICITIS; BENZIMIDAZOLES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; MIDDLE AGED; PATIENT DROPOUTS; PRURITUS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URTICARIA; VASCULITIS;

EID: 6544291728     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(98)00130-5     Document Type: Article

References (36)

1. Czarnetzki MB. Urticaria. Berlin: Springer-Verlag, 1986:26-45.
2. Mathews KP. The urticarias. Current concepts in pathogenesis and treatment. Drugs 1985;30:552-560.
3. Cooper KD. Urticaria and angioedema: diagnosis and evaluation. J Am Acad Dermatol 1991;25:166-167.
4. Ormerod AD. Urticaria. Recognition, causes and treatment. Drugs 1994;48:717-730.
5. 1 antihistamines in chronic urticaria. Ann Allerg 1993;71:585-591.
6. 1 Receptor antagonists. Comparative tolerability and safety. Drug Safety 1994;10:350-380.
7. 1-receptor antagonists. Clin Exp Allerg 1994;24:707-723.
8. Fredriksson I, Hersle K, Hjorth N, et al. Terfenadine in chronic urticaria, a comparison with clemastine and placebo. Cutis 1986;38:128-130.
9. Grant JA, Bernstein DI, Buckley CE, et al. Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. J Allerg Clin Immunol 1988;81:574-579.
10. Monroe EW, Bernstein DI, Fox RW, et al. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung 1992;42:1119-1121.
11. 1-receptor antagonist properties [abstract]. Eur J Pharmacol 1990;183:222.
12. Danjou P, Molinier P, Berlin I, et al. Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmacol 1992;34:328-331.
13. 1-receptor antagonist SL 85.0324 in rat and guinea pig [abstract]. Eur J Pharmacol 1990;183:218.
14. 1-receptor antagonist mizolastine in the rodent. Arzneimittelforschung 1995;45:559-568.
15. Rosenzweig P, Thébault JJ, Caplan H, et al. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Ann Allerg 1992;69:135-139.
16. Patat A, Gram LF, Dubruc C, et al. Effects of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjects. Int Clin Psychopharmacol 1994;9:101-108.
17. Pinquier J-L, Caplain H, Cabanis M-J, et al. Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine. J Clin Pharmacol 1996;36:72-78.
18. Rosenzweig P, Guillaume M, Brohier S, et al. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995;40:459-465.
19. Chaufour S, Ulliac N, Zieleniuk P, et al. Mizolastine, a new non-sedative H1 antagonist is devoid of CNS effects. A review of human pharmacology data [abstract] Allergy 1992;47(Suppl 12):154.
20. Kerr JS, Dunmore C, Hindmarch I. The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers. Eur J Clin Pharmacol 1994;47:331-335.
21. Patat A, Perrault MC, Vandel B, et al. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers. Br J Clin Pharmacol 1995;39:31-38.
22. Patat A, Stubbs D, Dunmore C, et al. Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects. Eur J Clin Pharmacol 1995;48:143-150.
23. Michel L, Murrieta-Aguttes M, Jean-Louis F, Dubertret L, Verrecchia M. Inhibitory effect of oral mizolastine (M) on in vivo antigen-induced soluble ICAM-1 release in human skin (skin chamber technique) (abstract P373). Allergy 1996;51(Suppl 31):117.
24. Brostoff J, Fitzharris P, Dunmore C, et al. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria Allergy 1996;51:320-325.
25. Motolese A, Carraro A, Montesano A, et al. Mizolastine (MZL) versus placebo (PLC) in chronic idiopathic urticaria (CIU) [abstract]. Allergy 1993;48(Suppl 16):38.
26. Ring J, Ingst R, Brockov K, et al. Mizolastine (M) in chronic idiopathic urticaric (CIU): a controlled placebo trial [abstract]. Allergy 1996;51(Suppl 31):165.
27. Leynadier C, Duarte-Risselin C, Murrieta M, et al. Comparative study of the therapeutic activity and safety of 10 mg mizolastine versus 10 mg loratadine in chronic idiopathic urticaria (CIU) [abstract]. Allergy 1995;50(Suppl 26):379-380.
28. Hamerlinck FFV, Boyden B, Oei HD, et al. A double-blind comparative study of loratadine and astemizole in chronic idiopathic urticaria. J Dermatol Treatment 1994;5:199-202.
29. Shareeah AMA. Comparative efficacy of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. Int J Dermatol 1992;31:355-356.
30. Ottevanger V, Niordson AM, Avrach W, et al. A comparison of loratadine and astemizole in the treatment of idiopathic chronic urticaria [abstract]. Allergy 1992;47(Suppl 12):50.
31. Palmieri G, Savasta C, de Bartolo G, et al. Loratadine in the management of chronic idiopathic urticaria. Acta Therapeut 1992;18:193-203.
32. Lazaro-Medina AL, Guytingco-Aquino MLR, Baltazar-Arcilla BU. An open study evaluating efficacy and safety of loratadine 10 mg once a day in idiopathic chronic urticaria. J Philippine Med Assoc 1990;65:272-279.
33. Funck-Brentano C, Jaillon P. Rate-corrected QT interval duration: techniques and limitations. Am J Cardiol 1993;72(Suppl B):1B-7B.
34. Fox RW, Lockey RF, Bukantz SC, et al. The treatment of mild to severe chronic idiopathic urticaria with astemizole: double-blind and open trials. J Allerg Clin Immunol 1986;78:1159-1166.
35. Belaich S, Bruttmann G, De Greef H, et al. Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allerg 1990;64:191-194.
36. 1 antagonist for the treatment of chronic idiopathic urticaria. J Allerg Clin Immunol 1986;77:37-42.